title: Allopurinol as a preventive contrivance after acute ischemic stroke in patients with a high level of serum uric acid: a randomized, controlled trial.
abstract: OBJECTIVE
  To assess the clinical relevance (functional outcome) of a 3-month allopurinol regimen in patients with high serum uric acid (SUA) levels and acute ischemic stroke without considering the changes in SUA levels.
  
  
  METHODS
  In a randomized, double-blind, controlled study, 70 patients (45 females, 25 males) with acute ischemic stroke who had elevated levels of SUA were included. They were divided in two 35-patient groups to investigate the effect of 3 months of an allopurinol (200 mg/day) regimen versus placebo on their functional outcome, which was evaluated using a modified Rankin scale.
  
  
  RESULTS
  The overall mean age was 68.9 ± 11.33 years (range 27-89). The final favorable functional status (mRS = 0-2) was 23 (65.7%) and 14 (40.0%) in the treated and placebo groups, respectively, which was strongly associated with allopurinol consumption (OR = 4.646, p = 0.014) and age ≤70 years (OR = 0.139, p = 0.005) in patients with ischemic stroke after adjusting for confounders. There was no significant difference in death between allopurinol-treated cases (3; 8.6%) and placebo-treated ones (6; 17.2%; p = 0.278).
  
  
  CONCLUSIONS
  Allopurinol treatment was well tolerated and improved the 3-month functional status of patients with acute ischemic stroke who had high levels of SUA without considering the decreasing effect of allopurinol on SUA.
authors.affiliation: Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Ali Akbar
authors.initials: AA
authors.lastname: Taheraghdam
authors.forename: Ehsan
authors.initials: E
authors.lastname: Sharifipour
authors.forename: Ali
authors.initials: A
authors.lastname: Pashapour
authors.forename: Shahryar
authors.initials: S
authors.lastname: Namdar
authors.forename: Abolfazl
authors.initials: A
authors.lastname: Hatami
authors.forename: Samaneh
authors.initials: S
authors.lastname: Houshmandzad
authors.forename: Elyar
authors.initials: E
authors.lastname: Sadeghihokmabadi
authors.forename: Mokhtar
authors.initials: M
authors.lastname: Tazik
authors.forename: Reza
authors.initials: R
authors.lastname: Rikhtegar
authors.forename: Ata
authors.initials: A
authors.lastname: Mahmoodpoor
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000493:Allopurinol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012737:Sex Factors; D020521:Stroke / Q000453:epidemiology*; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
chemical_list: D000493:Allopurinol; D014969:Xanthine Oxidase